Edition:
United States

Intellia Therapeutics Inc (NTLA.OQ)

NTLA.OQ on NASDAQ Stock Exchange Global Market

31.51USD
20 Sep 2018
Change (% chg)

-- (--)
Prev Close
$31.51
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
261,647
52-wk High
$35.99
52-wk Low
$16.33

Latest Key Developments (Source: Significant Developments)

Crispr Therapeutics, Intellia Therapeutics And Caribou Biosciences Provide Update On U.S Federal Circuit Decision
Monday, 10 Sep 2018 04:30pm EDT 

Sept 10 (Reuters) - Intellia Therapeutics Inc ::CRISPR THERAPEUTICS, INTELLIA THERAPEUTICS AND CARIBOU BIOSCIENCES PROVIDE UPDATE ON U.S FEDERAL CIRCUIT DECISION UPHOLDING THE RULING BY U.S. PATENT AND TRADEMARK OFFICE IN INTERFERENCE PROCEEDING RELATING TO CRISPR/CAS9 GENOME EDITING TECHNOLOGY.INTELLIA THERAPEUTICS INC - COMPANIES EXPECT USPTO WILL CONTINUE TO ISSUE PATENTS TO UC COVERING FOUNDATIONAL CRISPR/CAS9 TECHNOLOGY.  Full Article

Intellia Therapeutics Names John Leonard, M.D., President And CEO
Monday, 18 Dec 2017 07:30am EST 

Dec 18 (Reuters) - Intellia Therapeutics Inc ::INTELLIA THERAPEUTICS NAMES JOHN LEONARD, M.D., PRESIDENT AND CHIEF EXECUTIVE OFFICER.INTELLIA THERAPEUTICS INC - LEONARD SUCCEEDS NESSAN BERMINGHAM.  Full Article

Intellia Therapeutics prices public offering of 6.3 mln shares at $24 per share
Wednesday, 1 Nov 2017 09:00pm EDT 

Nov 1 (Reuters) - Intellia Therapeutics Inc :Intellia Therapeutics announces pricing of public offering of common stock.Says ‍priced public offering of 6.3 million shares of its common stock at a public offering price of $24.00 per share​.  Full Article

Intellia Therapeutics announces proposed public offering of common stock
Wednesday, 1 Nov 2017 07:00am EDT 

Nov 1 (Reuters) - Intellia Therapeutics Inc NTLA.O:Intellia therapeutics announces proposed public offering of common stock.Intellia therapeutics inc - ‍has commenced an underwritten public offering of $150 million of its common stock​.  Full Article

Intellia Therapeutics Q3 revenue $65 mln
Tuesday, 31 Oct 2017 07:30am EDT 

Oct 31 (Reuters) - Intellia Therapeutics Inc -:Intellia Therapeutics announces third quarter 2017 financial results.Q3 revenue $65 million.Q3 revenue view $5.9 million -- Thomson Reuters I/B/E/S.Says ‍well-tolerated safety profile observed for CRISPR/CAS9.  Full Article

Intellia Therapeutics Q3 loss per share $‍0.44​
Tuesday, 31 Oct 2017 07:30am EDT 

Oct 31 (Reuters) - Intellia Therapeutics Inc ::Intellia therapeutics announces third quarter 2017 financial results.Q3 collaboration revenue $7.3 million versus $4.9 million.Q3 revenue view $5.9 million -- Thomson Reuters I/B/E/S.Says ‍well-tolerated safety profile observed for CRISPR/Cas9.Qtrly loss per share $‍0.44​.Q3 earnings per share view $-0.50 -- Thomson Reuters I/B/E/S.  Full Article

Intellia Therapeutics reports Q2 revenue $69.6 million
Tuesday, 1 Aug 2017 07:30am EDT 

Aug 1 (Reuters) - Intellia Therapeutics Inc :Intellia Therapeutics announces second quarter 2017 financial results.Q2 revenue $69.6 million.Q2 revenue view $5.8 million -- Thomson Reuters I/B/E/S.Intellia Therapeutics Inc qtrly loss per share $0.45.Q2 earnings per share view $-0.42 -- Thomson Reuters I/B/E/S.Intellia Therapeutics - expect that cash, cash equivalents as of June 30 will enable co to fund operating expenses, capital expenditures through mid-2019.  Full Article

Intellia Therapeutics and San Raffaele University and Research Hospital to combine CRISPR/cas9 genome editing with enhanced cell therapies
Tuesday, 6 Jun 2017 07:15am EDT 

June 6 (Reuters) - Intellia Therapeutics Inc :Intellia Therapeutics and San Raffaele University And Research Hospital to combine CRISPR/cas9 genome editing with enhanced cell therapies to fight cancer.  Full Article

Intellia Therapeutics reports qtrly loss per share of $0.36
Tuesday, 2 May 2017 07:30am EDT 

May 2 (Reuters) - Intellia Therapeutics Inc : :Intellia Therapeutics announces first quarter 2017 financial results.Q1 collaboration revenue $6.2 million.Qtrly loss per share $0.36.Cash and cash equivalents at march 31, 2017, were $258 million, compared to $64 million for same quarter in 2016.During 2017, co expects expenses to continue to increase compared to prior periods.  Full Article

Intellia therapeutics announces European Patent Office's decision
Tuesday, 11 Apr 2017 07:30am EDT 

Intellia Therapeutics Inc : Intellia Therapeutics announces European Patent Office's decision to grant crispr/cas9 genome editing technology patent . Intellia Therapeutics - patent covers compositions of crispr single guide RNA technology for use in non-cellular, cellular settings, including eukaryotic cells . Intellia Therapeutics - EPO's decision to grant patent follows its March 24, notice of intent to issue patent, which was not challenged by any third party .Intellia Therapeutics - European patent will cover, approximately forty European countries, including Germany, Italy, France, Spain and Netherlands.  Full Article

BRIEF-Intellia Therapeutics Inc Q1 Loss Per Share $0.51

* INTELLIA THERAPEUTICS ANNOUNCES FIRST QUARTER 2018 FINANCIAL RESULTS